Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica

Journal of Veterinary Pharmacology and Therapeutics

Volumn 24, Issue 4, 2001, Pages 251-259

  Giorgi, M ^a   Salvatori, A P ^a   Soldani, G ^a   Giusiani, M ^b   Longo, V ^c   Gervasi, P G ^c   Mengozzi, G ^a  

^a Pharmacology and Toxicology Section ^*  (Italy)

^b Toxicology Section   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA TESTOSTERONE HYDROXYLASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; EPSIPRANTEL; ERYTHROMYCIN N DEMETHYLASE; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DEHYDROGENASE; IDITOL DEHYDROGENASE; NEOMANSONIL; PRAZIQUANTEL; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISPOSITION; DRUG OXIDATION; FASCIOLIASIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LAMB; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANTHELMINTICS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FASCIOLA HEPATICA; FASCIOLIASIS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; INJECTIONS, INTRAMUSCULAR; MALE; MICROSOMES, LIVER; OXIDATION-REDUCTION; PRAZIQUANTEL; SHEEP; SHEEP DISEASES;

ANIMALIA; FASCIOLA HEPATICA; HEPATICA; OVIS ARIES; STAPHYLOCOCCUS PHAGE 3A;

EID: 0034864436     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.2001.00341.x     Document Type: Article

References (46)

1. Metabolism studies of the antischistosomal drug praziquantel using Tandem Mass Spectrometry: Qualitative identification of 17 hydroxylated metabolites from mouse urine
2. Metabolism studies of the antischistosomal drug praziquantel using Tandem Mass Spectrometry: Distribution of parent drug and ten metabolites obtained from control and schistosome-infected mouse urine
3. Praziquantel: Mechanisms of anti-schistosomal activity
4. Praziquantel
5. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel
6. Species variation in the response of the cytochrome P450 dependent monooxygenase system to inducers and inhibitors
7. Treatment of cysticercosis with praziquantel in Columbia
8. Metabolism of praziquantel in man
9. Infestioni da Moniezia sp. nella pecora. Trattamento con il praziquantel
10. The fate of praziquantel in the organism III. Metabolism in rat, beagle dog and rhesus monkey
11. Results of toxicological studies on praziquantel
12. Pharmacological basis for hepatic drug metabolism in sheep
13. Impairment of drug metabolism by the liver in experimental fascioliasis in the rat
14. Incidence of experimental fascioliasis on the activity of drug-metabolizing enzymes in lamb liver
15. Praziquantel for cestode infections in man
16. Praziquantel
17. The anthelmintic action of praziquantel
18. Microsomal oxidation of praziquantel
19. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single day therapeutic regimen
20. Clinical pharmacokinetics of praziquantel
21. Comparison of hepatic drug metabolising enzymes in three month old lambs and kids
22. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity
23. An alternative 7-ethoxyresorufin assay: A continuous visible spectrophotometric method for measurement of cytochrome P450 monooxygenase activity
24. Monoclonal antibodies to ethanol-induced cytochrome P450 that metabolize aniline and nitrosamines
25. Effect of experimentally induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in rats
26. Selective induction of renal microsomal cytochrome P450-linked monooxygenases by 1,1-dichloroethylene in mice
27. Drug metabolizing enzymes in liver, olfactory and respiratory epithelium of cattle
28. Protein measurement with the Folin phenol reagent
29. Decrease of the in vitro drug-metabolising activity of the hepatic mixed function oxidase system in rat infected experimentally with Fasciola hepatica: Pharmacological implication
30. Characterization of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors
31. Effects of Phenobarbital and 3-methylcholanthrene pre-treatment on the pharmacokinetics of praziquantel in rats
32. Comparison of Albendazole and Praziquantel therapy of Echinococcus granulosus in naturally infected sheep
33. The carbon-monoxide binding protein of liver microsomes. I. Evidences for its hemoprotein nature
34. Inhibition of Cytochrome P450 Enzymes
35. Praziquantel: A major advance in anthelmintic therapy
36. Purification of a sheep liver cytochrome P450 from the P450IIIA gene subfamily. Its contribution to the n-dealkylation of veterinary drugs
37. Genetically engineered V79 Chinese hamster cell expression of purified cytochrome P450IIB1 monooxygenase activity
38. p-Nitrophenol hydroxylation, a microsomal oxidation which is highly inducible by ethanol
39. Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes
40. Cytochrome P450 sex differences in minipig and conventional pig
41. Speculations on the substrate structure-activity relationship (SSAR) of the cytochrome P450 enzymes
42. The fate of praziquantel in the organism. I. Pharmacokinetics in animals
43. High-affinity nitrosamine dealkylase system in rat liver microsomes and its induction by fasting
44. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously
45. Quantitative determination of praziquantel in serum by high-performance liquid chromatography
46. Plasma pharmacokinetics and therapeutic efficacy of praziquantel and 4-hydroxypraziquantel in Schistosoma japonicum-infected rabbits after oral, rectal, and intramuscular administration